Advertisement
Cardiovascular
Subscribe to Cardiovascular
View Sample

FREE Email Newsletter

New Highmark Policy Threatens Pennsylvania Patients With Primary Immunodeficiency Diseases

March 16, 2011 11:32 am | by Bio-Medicine.Org | News | Comments

HARRISBURG, Pa., March 16, 2011 /- Beginning April 1, Highmark Blue Cross Blue Shield (Highmark) will force their insured patients with primary immunodeficiency diseases (PIDD) and other rare disorders to switch their prescription to a single brand of immunoglobulin (IgG - a blood plasma...

Global Blood Processing Supplies And Equipment Industry

March 16, 2011 11:32 am | by Bio-Medicine.Org | News | Comments

NEW YORK, March 16, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Global Blood Processing Supplies And Equipment Industry http://www.reportlinker.com/p087335/Global-Blood-Processing-Supplies-And-Equipment-Industry.html This report...

Aegerion gains orphan drug status for lipid disorder drug

March 16, 2011 10:35 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Aegerion Pharmaceuticals Inc., a lipid disorder treatment firm in Cambridge, has been granted orphan drug designation from the U.S. Food and Drug Administration for its treatment of familial chylomicronemia (FC), a rare genetic disorder.

Advertisement

Akrimax Pharmaceuticals, LLC, Introduces NitroMist® (Nitroglycerin Lingual Aerosol) 400mcg/Spray

March 16, 2011 1:35 am | by Bio-Medicine.Org | News | Comments

CRANFORD, N.J., March 16, 2011 /- Coronary artery disease (CAD), also known as coronary heart disease, is the most common type of heart disease, currently affecting about 17 million Americans(1). Most of these people suffer from a common symptom of CAD known as angina pectoris. For over...

BD Donates $325,000 for Japan Earthquake and Tsunami Relief Efforts

March 15, 2011 11:34 am | by Bio-Medicine.Org | News | Comments

FRANKLIN LAKES, N.J., March 15, 2011 /- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it is donating $325,000 to assist in relief efforts for victims of the earthquake and tsunami in Japan. BD will distribute these funds...

Electricity Sparks Interest in New Technologies and Cosmeceuticals for Aging Skin

March 15, 2011 8:32 am | by Bio-Medicine.Org | News | Comments

SCHAUMBURG, Ill., MARCH 15, 2011/PRNewswire-USNewswire/ -- It may seem as if new developments to combat aging skin are being introduced faster than the speed of light. At the forefront of the research, dermatologists are underpinning these advancements, refining the basic understanding of...

FDA Approves Gadavist for Central Nervous System Scans

March 15, 2011 7:33 am | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., March 15, 2011 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration approved Gadavist (gadobutrol), a gadolinium-based contrast agent, for use in patients undergoing magnetic resonance imaging (MRI) of the central nervous system. (Logo:...

Pradaxa Gains Preferred Formulary Status with Key Pharmacy Benefit Managers

March 14, 2011 1:33 pm | by Bio-Medicine.Org | News | Comments

RIDGEFIELD, Conn., March 14, 2011 /- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI), today announced that Pradaxa® (dabigatran etexilate mesylate) capsules has received preferred Tier 2 formulary status with CVS Caremark (Commercial Preferred Drug List) and Medco (Commercial...

Advertisement

New Aid for AIDS - ICAP Ocean Tomo Announces Auction of a Keystone Patent for Cell Therapy Use of Modified Red Blood Cells for Treating Viral Diseases

March 14, 2011 9:35 am | by Bio-Medicine.Org | News | Comments

CHICAGO, March 14, 2011 /- Developed by inventor Lawrence F. Glaser and represented by ICAP Ocean Tomo , this technology will be auctioned off at ICAP Ocean Tomo's Spring 2011 Live IP Auction on March 31, 2011 in New York City. (Logo:  ...

OrbusNeich Announces Availability of Azuleâ„¢ Cobalt Chromium Stent

March 14, 2011 6:34 am | by Bio-Medicine.Org | News | Comments

HONG KONG, March 14, 2011 /- OrbusNeich today announced the launch of the CE marked Azule Cobalt Chromium Stent.  The Azule Stent combines the proven stent design of its predecessor, the company's Blazer™ Cobalt Chromium Stent, with a delivery system with enhanced crossability...

Transgenomic Expands COLD-PCR License

March 14, 2011 6:33 am | by Bio-Medicine.Org | News | Comments

OMAHA, Neb., March 14, 2011 /- Transgenomic, Inc. (OTC Bulletin Board: TBIO ) today announced the completion of an expanded license with the Dana-Farber Cancer Institute, Boston, MA, for the COLD-PCR (CO-amplification at Lower Denaturing temperature PCR) technology. Previously,...

Covidien Receives FDA Approval for South African-Produced Medical Isotope Based on Low-Enriched Uranium

March 11, 2011 4:34 pm | by Covidien | News | Comments

ST. LOUIS, Mar 10, 2011 (BUSINESS WIRE) --Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of molybdenum-99 (Mo-99) derived from low-enriched uranium (LEU) in the production of...

Improvements in Pressure Sensors Help Medical Equipment Design

March 11, 2011 11:17 am | by David Ezekiel | Articles | Comments

Goals of new medical equipment design include small size, low cost, low power consumption, and a quiet user experience. Evolving technology embedded in pressure sensors and signal conditioning ICs allows for design improvements and the inclusion of new features in medical equipment. This article highlights specific examples in the design of breathing equipment and oxygen concentrators.

Advertisement

Woman Files Suit in Beaumont, Texas Federal Court Against DePuy Orthopaedics and Johnson & Johnson Over Recalled Hip Device

March 11, 2011 4:33 am | by Bio-Medicine.Org | News | Comments

LIBERTY, Texas, March 10, 2011 /- Donna L. Jenkins filed suit today in the United States District Court in Beaumont, Texas, over a failed hip replacement system from Johnson & Johnson, Inc. and DePuy Orthopaedics that was recalled from the market.  John David Hart of the Law...

Texas Children's Is First Pediatric Hospital To Begin Certification Process for SynCardia's Total Artificial Heart

March 10, 2011 7:34 am | by Bio-Medicine.Org | News | Comments

HOUSTON, March 10, 2011 /PRNewswire-USNewswire/ -- Texas Children's Hospital and SynCardia Systems, Inc. announced today that Texas Children's has become the world's first pediatric hospital to complete the first phase of certification to implant the SynCardia temporary Total Artificial...

Reportlinker Adds Advances in SPECT Imaging (Technical Insights)

March 9, 2011 7:34 am | by Bio-Medicine.Org | News | Comments

NEW YORK, March 9, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Advances in SPECT Imaging (Technical Insights) http://www.reportlinker.com/p0443053/Advances-in-SPECT-Imaging-Technical-Insights.html This research service evaluates the...

13 Novel Genetic Components of Coronary Artery Disease Identified

March 8, 2011 6:34 am | by University Of Pennsylvania | News | Comments

An international analysis of 14 genome-wide association studies involving over 100,000 patients has identified 13 new genetic risk factors for coronary artery disease (CAD). Muredach P. Reilly, MBBCH, MSCE, associate professor of Medicine, University of Pennsylvania School of Medicine,...

Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11

March 8, 2011 4:35 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, March 8, 2011 /- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) today announced it will report fourth quarter and full year 2010 financial results before the NASDAQ Global Select Market opens on Friday, March 11, 2011. That same morning, Jack Lief, Arena's President and Chief...

RainDance Technologies and Ambry Genetics Expand Collaboration to Address ADME Analysis

March 7, 2011 7:33 am | by Bio-Medicine.Org | News | Comments

WASHINGTON, March 7, 2011 /- RainDance Technologies, Inc. and Ambry Genetics, today announced a new collaboration focused on the development and commercialization of a comprehensive drug absorption, distribution, metabolism, and excretion (ADME) genetic screening panel for use on...

Xeridiem Medical Devices Appoints Renae Moomjian, Vice President, Business Development

March 7, 2011 7:33 am | by Bio-Medicine.Org | News | Comments

TUCSON, Ariz., March 7, 2011 /- Xeridiem Medical Devices strengthened its executive team with the appointment of Renae Moomjian, Vice President, Business Development. Joseph Lee, Xeridiem Medical Devices' President said, "I am pleased to announce that Renae Moomjian has joined Xeridiem...

Boston Scientific Announces European Approval and Launch of OMEGAâ„¢ Platinum Chromium Stent System

March 7, 2011 4:34 am | by Bio-Medicine.Org | News | Comments

NATICK, Mass., March 7, 2011 /- Boston Scientific Corporation (NYSE: BSX ) today announced it has received CE Mark for its OMEGA™ Platinum Chromium Bare-Metal Coronary Stent System, the Company's third-generation coronary stenting technology.  It incorporates Boston...

Isis Pharmaceuticals to Present at the Roth 23rd Annual OC Growth Stock Conference

March 7, 2011 4:33 am | by Bio-Medicine.Org | News | Comments

CARLSBAD, Calif., March 7, 2011 /- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ), the leader in antisense therapeutics, today announced that management will present a company overview at Roth's 23rd Annual OC Growth Stock Conference on Monday, March 14, 2011 at 1:00 p.m. PT at the Ritz...

Boston Scientific Strengthens Structural Heart Product Portfolio By Completing Acquisition of Atritech

March 3, 2011 3:35 am | by Boston Scientific | News | Comments

Company adds innovative technology for atrial fibrillation patients with high stroke risk

Nile Therapeutics Receives Positive NASDAQ Panel Decision

March 2, 2011 3:35 am | by Bio-Medicine.Org | News | Comments

SAN MATEO, Calif., March 2, 2011 /- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company focused on the development of novel therapeutics for heart failure patients, today announced that, on March 1, 2011, the Company received a positive determination from the NASDAQ Listing Qualifications...

Harris Corporation Awarded Contract to Provide Engineering and Enterprise Support to Veteran Affairs's VistA Imaging System

March 2, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

MELBOURNE, Fla. and WASHINGTON, March 2, 2011 /- Highlights: System serves more than 1.3 million patients and captures more than 35 million images each month Critical component of VA's mission to provide multimedia patient health records at point of care One of the most comprehensive and...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading